The device aids in detecting early melanoma.
MELA Sciences said it intend to first market the device in Germany, which has the highest incidence of melanoma in Europe. More than 20,000 Germans are expected to be diagnosed with melanoma by 2016.
Also today, St. Jude Medical (NYSE:STJ) said the European Union has approved its implanted Genesis neurostimulation device for patients with intractable chronic migraine.
And Novartis (NYSE:NVS) is seeing strong volume today.
Perhaps investors are looking at a Wall Street Journal report that says a Food & Drug Administration advisory panel will consider whether women taking certain bone-loss prevention drugs should limit their treatment period or take a ''drug holiday'' to prevent thigh fractures and jaw bone decay. Novartis makes one of the bisphosphonate drugs, as does Warner Chilcott (NASDAQ:WCRX), the Journal noted.
For MarketNewsVideo.com, I'm Kristin Bianco.
All videos » Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer. 
No comments:
Post a Comment